{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-034714","form_type":"8-K","ticker":"ASBP","cik":"0001847345","company_name":"Aspire Biopharma Holdings, Inc.","filed_at":"2024-09-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.883007+00:00","generated_at":"2026-05-31T06:40:44.676195+00:00","sec_items":["8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PowerUp Acquisition announces definitive merger with Aspire Biopharma at $316M pre-money valuation","bullets":["Pre-money equity value of Aspire approximately $316 million.","Combined company to be named 'Aspire Biopharma Holdings, Inc.' and list on Nasdaq under 'ASPH'.","Existing Aspire shareholders expected to retain majority ownership after closing.","Expected closing end of Q4 2024 or beginning of Q1 2025; subject to regulatory and stockholder approvals.","Aspire's lead product Instaprin (soluble aspirin) targeting 505(b)(2) NDA with FDA."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-034714","json":"https://secwatch.observer/filing/0001493152-24-034714.json","markdown":"https://secwatch.observer/filing/0001493152-24-034714.md","text":"https://secwatch.observer/filing/0001493152-24-034714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847345/000149315224034714/0001493152-24-034714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847345/000149315224034714/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:40:44.676195+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}